Flierl, UlrikeNero, T.LLim, BAndrews, Robert KParker, Michael WilliamGardiner, ElizabethPeter, Karlheinz2021-12-081538-7933http://hdl.handle.net/1885/255030Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.application/pdfen-AU© 2017 International Society on Thrombosis and Haemostasis201810.1111/jth.138772023-10-29